February 9, 2026
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

IV Brincidofovir Phase 2 Clinical Trial Results in CMV Infection Following Hematopoietic Stem Cell Transplantation Presented Orally at the Tandem Meetings

SymBio Pharmaceuticals Limited (the "Company") today announced that the results from its Phase 2 clinical trial of IV BCV (intravenous brincidofovir) in cytomegalovirus (CMV) infection in immunocompromised patients following hematopoietic stem cell transplantation were orally presented at the Tandem Meetings held in Utah, USA (February 4–7, 2026).

The trial enrolled 19 patients who were immunocompromised following hematopoietic stem cell transplantation and had persistent CMV DNAemia despite multiple prior therapies. Patients received IV BCV twice weekly at different dose levels to evaluate efficacy and safety.

Summary of the IV BCV Phase 2 clinical trial results:

- IV BCV showed an effect in reducing CMV DNAemia and demonstrated good tolerability.
- IV BCV may be a treatment option with expected clinical benefit for patients with CMV infection who have limited treatment options.

Statement from Fuminori Yoshida, Representative Director, President and CEO:
"The favorable results observed in patients with a history of multiple prior therapies support development for the treatment of CMV infection. Based on these findings, we will continue our evaluation for immunocompromised patients with CMV infection who have no treatment options."

These results were submitted as a Late-Breaking Abstract and were presented orally by Dr. Fareed Khawaja of The University of Texas MD Anderson Cancer Center. While several treatments options are available, significant unmet medical needs persist in

CMV treatment, as many patients fail to achieve optimal outcomes. Consequently, there is a high level of clinical interest among healthcare professionals for data regarding IV BCV.

Presentation Overview

- Abstract ID & Title: 29614: Intravenous Brincidofovir Effectively Reduces CMV DNAemia in Antiviral-Experienced Immunocompromised Patients: Results of a Phase 2a Clinical Trial
- Presenting Author: Dr Fareed Khawaja (MD Anderson, Houston Texas, USA)
- Session: Late-Breaking Abstracts
- Session Date/Time: Saturday, February 7, 2026, 3:15 PM MST

Notes

Tandem Meetings

The Tandem Meetings are the combined annual conferences of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). This major event focuses on hematopoietic cell transplantation (HCT) and cellular therapy, which inherently involve highly immunocompromised patient populations.

Treatment of CMV Infection and Disease

When antiviral agents are used to prevent CMV infection and disease, there are mainly two approaches. The first is universal prophylaxis, in which antiviral agents are administered on a scheduled basis to all eligible patients after hematopoietic recovery. The second is preemptive therapy, in which CMV reactivation is continuously monitored and antiviral therapy is initiated when test results exceed predefined thresholds. Although effective therapies exist, reactivation occurs in a substantial number of cases, and there are cases of resistance or non-response to antiviral drugs. Because this remains an area of unmet need, medical needs are extremely high and new treatments are strongly desired.

BCV's Business Strategy Based on Three Therapeutic Pillars

Since acquiring the global license to BCV in September 2019, SymBio has been conducting collaborative research with world-class research institutions to unlock BCV's potential in three therapeutic areas. Currently, our management resources and development efforts are centered on three therapeutic pillars: (1) viral infections post-

HSCT, (2) hematologic malignancies and solid tumors, and (3) neurodegenerative diseases. SymBio is focusing on its business globally to maximize the business value of BCV.